title: Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
abstract: BACKGROUND
  We compared stable patients with schizophrenia who were treated with either amisulpride or olanzapine in terms of symptomatic outcome, neurocognitive functioning, functionality, and subjective outcome.
  
  
  METHODS
  Sixty outpatients with chronic schizophrenia who had been treated with either amisulpride or olanzapine for at least six months were investigated.
  
  
  RESULTS
  The scores of positive, negative, and cognitive symptoms did not differ between the two groups, but patients treated with olanzapine had significantly lower scores on the excitement and depression/anxiety components of the PANSS. With regard to cognitive variables, patients treated with amisulpride showed significantly lower values regarding verbal fluency and significantly better verbal memory than patients treated with olanzapine. Both treatment groups were comparable with respect to functional and subjective outcome variables.
  
  
  CONCLUSIONS
  These observations add to the evidence that continuous treatment with different second-generation antipsychotics with relatively few side effects leads to comparable outcomes in patients with schizophrenia.
authors.affiliation: Department of Biological Psychiatry, Innsbruck Medical University, Austria. a.hofer@i-med.ac.at
authors.forename: A
authors.initials: A
authors.lastname: Hofer
authors.forename: M A
authors.initials: MA
authors.lastname: Rettenbacher
authors.forename: M
authors.initials: M
authors.lastname: Edlinger
authors.forename: R
authors.initials: R
authors.lastname: Huber
authors.forename: T
authors.initials: T
authors.lastname: Bodner
authors.forename: G
authors.initials: G
authors.lastname: Kemmler
authors.forename: G
authors.initials: G
authors.lastname: Sachs
authors.forename: W W
authors.initials: WW
authors.lastname: Fleischhacker
mesh_terms: D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D000077152:Olanzapine; D010045:Outpatients; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012919:Social Behavior; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D013469:Sulpiride; D000077582:Amisulpride; D000077152:Olanzapine